Joaquin Valdes

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Kenneth B. Gordon, Bruce Strober, Mark Lebwohl et al. · The Lancet · 2018 · 662 citations

Medicine, Clinical Sciences, Pharmacotherapy +11

A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease

Sven A. Danner, Andrew Carr, John M. Leonard et al. · New England Journal of Medicine · 1995 · 573 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection

Martin Markowitz, Michael S. Saag, William G. Powderly et al. · New England Journal of Medicine · 1995 · 492 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Xavier Forns, Samuel S. Lee, Joaquin Valdes et al. · The Lancet Infectious Diseases · 2017 · 343 citations

Medicine, Infectious Diseases, Pharmacotherapy +14

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

Dale J. Kempf, Richard A. Rode, Yi Xu et al. · AIDS · 1998 · 224 citations

Life Sciences, Infectious Diseases, Pharmacology +17